Tickers — V

Viking Therapeutics provides unparalleled, multi-bagger upside as the premier independent disruptor in the $100B+ obesity market and a prime Big Pharma M&A target, severely counterbalanced by the existential threat of intolerable oral pill toxicity and hostile IP litigation stripping its secondary assets.

Vistra offers a deeply undervalued, heavily hedged cash-printing monopoly poised to monopolize the AI data center energy supercycle, though a massive $20.5B debt load and acute exposure to hostile regulatory shifts regarding nuclear PPAs remain persistent tail risks.